Pain Therapeutics Phase I Study Positive
November 29, 2006 · Filed Under General
Pain Therapeutics (PTIE) announced early on Wednesday that its phase I clinical study of the abuse resistant opioid painkiller, PTI-202, showed positive results.
The study was aimed at investigating the safety and tolerability of PTI-202.
The company is focused on research and development of its opioid painkiller portfolio that exhibit non-abuse potential as compared to traditional opioids on the market.
Pain Therapeutics was chosen as a BioHealth Investor Stock Pick back on November 19.
Comments
Leave a Reply
You must be logged in to post a comment.